Mga Batayang Estadistika
| CIK | 1463729 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Receptos, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 8, 2015 |
Form 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35900 RECEPTOS, INC. (Exact name of Registrant as specified i |
|
| August 27, 2015 |
S-8 POS As filed with the Securities and Exchange Commission on August 27, 2015 Registration No. |
|
| August 27, 2015 |
S-8 POS 1 d63898ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on August 27, 2015 Registration No. 333-189552 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RECEPTOS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-4190792 (Sta |
|
| August 27, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2015 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation) (Commission |
|
| August 27, 2015 |
As filed with the Securities and Exchange Commission on August 27, 2015 Registration No. |
|
| August 25, 2015 |
Celgene AMENDMENT NO. 3 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) RECEPTOS, INC. (Name of Subject Company (Issuer)) STRIX CORPORATION (Offeror) A Wholly-Owned Subsidiary of CELGENE CORPORATION (Parent of Offeror) (Names of Filing Persons (identifying s |
|
| August 25, 2015 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RECEPTOS, INC. (Name of Subject Company) RECEPTOS, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 756207106 (CUSIP Number |
|
| August 25, 2015 |
Celgene Announces Expiration of Cash Tender Offer for Shares of Receptos, Inc. EX-99.(A)(5)(G) 2 t1502009exa5g.htm EXHIBIT (A)(5)(G) Exhibit (a)(5)(G) Contact: Patrick E. Flanigan III Brian Gill VP, Investor Relations VP, Corporate Communications Celgene Corporation Celgene Corporation (908) 673-9969 (908) 673-9530 Celgene Announces Expiration of Cash Tender Offer for Shares of Receptos, Inc. SUMMIT, NJ – (August 25, 2015) – Celgene Corporation (NASDAQ:CELG) today announced |
|
| August 18, 2015 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RECEPTOS, INC. (Name of Subject Company) RECEPTOS, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 756207106 (CUSIP Number |
|
| August 18, 2015 |
Celgene AMENDMENT NO. 2 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) RECEPTOS, INC. (Name of Subject Company (Issuer)) STRIX CORPORATION (Offeror) A Wholly-Owned Subsidiary of CELGENE CORPORATION (Parent of Offeror) (Names of Filing Persons (identifying s |
|
| August 11, 2015 |
Celgene Receives Antitrust Clearance for Receptos Acquisition Exhibit (a)(5)(F) Celgene Receives Antitrust Clearance for Receptos Acquisition SUMMIT, N. |
|
| August 11, 2015 |
Celgene AMENDMENT NO. 1 TO SCHEDULE TO SC TO-T/A 1 t1501851scto-a.htm AMENDMENT NO. 1 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) RECEPTOS, INC. (Name of Subject Company (Issuer)) STRIX CORPORATION (Offeror) A Wholly-Owned Subsidiary of CELGENE CORPORATI |
|
| August 11, 2015 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RECEPTOS, INC. (Name of Subject Company) RECEPTOS, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 756207106 (CUSIP Number |
|
| July 30, 2015 |
Receptos 10-Q (Quarterly Report) 10-Q 1 rcpt-10q20150630.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35900 RECEPTOS, INC |
|
| July 30, 2015 |
Exhibit 10.3 AGREEMENT This AGREEMENT (the “Agreement”), dated as of July 14, 2015, is made and entered into by and between Receptos, Inc., a Delaware corporation (the “Company”), and William H. Rastetter, Ph.D. (the “Rastetter”). WHEREAS, the Company, Celgene Corporation, a Delaware corporation (“Parent”), and Strix Corporation, a Delaware corporation and direct wholly owned subsidiary of Parent |
|
| July 28, 2015 |
t1501695-sctoDIV03-ex-a1c - none - 2.2142214s ? Exhibit (a)(1)(C)? NOTICE OF GUARANTEED DELIVERY To Tender Shares of Common Stock of RECEPTOS, INC. at $232.00 Net Per Share by STRIX CORPORATION a wholly-owned subsidiary of CELGENE CORPORATION This form, or a substantially equivalent form, must be used to accept the Offer (as defined below) if certificates representing tendered Shares (as defined b |
|
| July 28, 2015 |
SC 14D9 1 d51890dsc14d9.htm SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RECEPTOS, INC. (Name of Subject Company) RECEPTOS, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Cla |
|
| July 28, 2015 |
Receptos, Inc. 3033 Science Park Road, Suite 300 San Diego, CA 92121 EX-99.A9 Exhibit (a)(9) Receptos, Inc. 3033 Science Park Road, Suite 300 San Diego, CA 92121 July 28, 2015 Dear Stockholder: We are pleased to inform you that, on July 14, 2015, Receptos, Inc. (?Receptos?) entered into a definitive Agreement and Plan of Merger (the ?Merger Agreement?) with Celgene Corporation (?Parent?) and Strix Corporation, a wholly owned subsidiary of Parent (?Purchaser?). In a |
|
| July 28, 2015 |
t1501695-scto - none - 2.3952395s ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ? RECEPTOS, INC. (Name of Subject Company (Issuer)) STRIX CORPORATION (Offeror) A Wholly-Owned Subsidiary of CELGENE CORPORATION (Parent of Offeror) (Names of Fil |
|
| July 28, 2015 |
EX-99.E20 Exhibit (e)(20) AGREEMENT This AGREEMENT (the ?Agreement?), dated as of July 14, 2015, is made and entered into by and between Receptos, Inc., a Delaware corporation (the ?Company?), and William H. Rastetter, Ph.D. (the ?Rastetter?). WHEREAS, the Company, Celgene Corporation, a Delaware corporation (?Parent?), and Strix Corporation, a Delaware corporation and direct wholly owned subsidia |
|
| July 28, 2015 |
RECEPTOS. INC. NONDISCLOSURE AGREEMENT EX-99.D3 9 t1501695ex-d3.htm EXHIBIT (D)(3) Exhibit (d)(3) RECEPTOS. INC. NONDISCLOSURE AGREEMENT This NONDISCLOSURE AGREEMENT (the “Agreement”), dated as of August 28, 2013 (the “Effective Date”), is entered into by and between Receptos, Inc., a Delaware corporation having its principal place of business at 10835 Road to the Cure, Suite #205, San Diego, CA 92121 (“Receptos”), and Celgene Corporat |
|
| July 28, 2015 |
EX-99.A5D 7 t1501695ex-a5d.htm EXHIBIT (A)(5)(D) Exhibit (a)(5)(D) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely by the Offer to Purchase (as defined below), dated July 28, 2015, and the related Let |
|
| July 28, 2015 |
t1501695-sctoDIV01-ex-a1a - none - 4.0844084s TABLE OF CONTENTS July 28, 2015 Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Receptos, Inc. at $232.00 Net Per Share by Strix Corporation? a wholly-owned subsidiary of ? Celgene Corporation ? ? ? THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, AT THE END OF THE DAY ON MONDAY, |
|
| July 28, 2015 |
t1501695-sctoDIV05-ex-a1e - none - 2.2882288s ? Exhibit (a)(1)(E)? Offer to Purchase for Cash All Outstanding Shares of Common Stock of RECEPTOS, INC. at $232.00 Net Per Share by STRIX CORPORATION a wholly-owned subsidiary of CELGENE CORPORATION THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, AT THE END OF THE DAY, MONDAY, AUGUST 24, 2015, UNLESS THE OFFER IS EXTENDED |
|
| July 28, 2015 |
EX-99.E21 Exhibit (e)(21) Excerpts from the Receptos, Inc. Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 17, 2015. Board of Directors The names of our directors, their ages and their positions with the Company as of April 2, 2015 are set forth below. Name Age Position(s) William H. Rastetter, Ph.D. 67 Chairman of the Board of Directors Krist |
|
| July 28, 2015 |
EX-99.A1D 5 t1501695ex-a1d.htm EXHIBIT (A)(1)(D) Exhibit (a)(1)(D) Offer to Purchase for Cash All Outstanding Shares of Common Stock of RECEPTOS, INC. at $232.00 Net Per Share by STRIX CORPORATION a wholly-owned subsidiary of CELGENE CORPORATION THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, AT THE END OF THE DAY ON MONDAY, AUGUST 24, 2015, UNLESS THE OFFER IS EXTEND |
|
| July 28, 2015 |
t1501695-sctoDIV02-ex-a1b - none - 2.2272227s ? Exhibit (a)(1)(B)? Letter of Transmittal To Tender Shares of Common Stock of RECEPTOS, INC. at $232.00 Net Per Share in Cash Without Interest Pursuant to the Offer to Purchase dated July 28, 2015 by Strix Corporation, a wholly-owned subsidiary of Celgene Corporation The undersigned represents that I (we) have full authority to surrender without restr |
|
| July 28, 2015 |
Celgene Corporation Commences Tender Offer for Receptos, Inc. t1501695-sctoDIV07-ex-a5e - none - 1.6811681s ? Exhibit (a)(5)(E)? ? Celgene Corporation Commences Tender Offer for Receptos, Inc. SUMMIT, NJ???Celgene Corporation (NASDAQ: CELG) today announced that its direct wholly-owned subsidiary, Strix Corporation, has commenced its previously announced tender offer for all outstanding shares of common stock of Receptos, Inc. (NASDAQ: RCPT) at a price of? $2 |
|
| July 17, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 17, 2015 CELGENE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-34912 22-2711928 (State or other jurisdiction of incorporation) (Commission File |
|
| July 16, 2015 |
EX-2.1 2 d62138dex21.htm EX-2.1 Exhibit 2.1 Execution Copy AGREEMENT AND PLAN OF MERGER by and among CELGENE CORPORATION, STRIX CORPORATION and RECEPTOS, INC. Dated as of July 14, 2015 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 2 1.1 Certain Definitions 2 1.2 Additional Definitions 13 1.3 Certain Interpretations 15 ARTICLE II THE OFFER 16 2.1 The Offer 16 2.2 Company Actions 21 |
|
| July 16, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2015 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation) (Commission F |
|
| July 16, 2015 |
EX-99.1 Exhibit 99.1 Execution Version TENDER AND SUPPORT AGREEMENT by and among CELGENE CORPORATION, STRIX CORPORATION, and EACH OF THE STOCKHOLDERS NAMED HEREIN Dated as of July 14, 2015 TENDER AND SUPPORT AGREEMENT THIS TENDER AND SUPPORT AGREEMENT, dated as of July 14, 2015 (this ?Agreement?), by and among Celgene Corporation, a Delaware corporation (?Parent?), Strix Corporation, a Delaware co |
|
| July 16, 2015 |
FORM OF AMENDMENT TO [AMENDED AND RESTATED] EMPLOYMENT AGREEMENT EX-10.1 3 d62138dex101.htm EX-10.1 Exhibit 10.1 FORM OF AMENDMENT TO [AMENDED AND RESTATED] EMPLOYMENT AGREEMENT This AMENDMENT TO [AMENDED AND RESTATED] EMPLOYMENT AGREEMENT (the “Amendment”), dated as of [ ], is made and entered into by and between Receptos, Inc., a Delaware corporation (the “Company”), and [ ] (the “Executive”). RECITALS WHEREAS, the Company, Celgene Corporation, a Delaware cor |
|
| July 15, 2015 |
THOMSON REUTERS STREETEVENTS | Exhibit 99.1 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT CELG - Celgene to Acquire Receptos M&A Call EVENT DATE/TIME: JULY 14, 2015 / 09:30PM GMT 1 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ? 2015 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written |
|
| July 15, 2015 |
EX-99.1 4 t1501623ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Execution Version TENDER AND SUPPORT AGREEMENT by and among CELGENE CORPORATION, STRIX CORPORATION, and EACH OF THE STOCKHOLDERS NAMED HEREIN Dated as of July 14, 2015 TENDER AND SUPPORT AGREEMENT THIS TENDER AND SUPPORT AGREEMENT, dated as of July 14, 2015 (this “Agreement”), by and among Celgene Corporation, a Delaware corporation (“Parent”) |
|
| July 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 RECEPTOS, INC. (Name of Subject Company (Issuer)) STRIX CORPORATION (Offeror) A Wholly Owned Subsidiary of CELGENE CORPORATION (Parent of Offeror) (Names of Filing Persons (identifying status as offeror, issuer or other |
|
| July 15, 2015 |
Celgene Announces Acquisition of Receptos July 14, 2015 Exhibit 99.1 Celgene Announces Acquisition of Receptos July 14, 2015 Agenda 2 Bob Hugin, Celgene Chairman & Chief Executive Officer ? Strategic Overview Scott Smith, Celgene President of Global Inflammation and Immunology ? Enhancing the I&I Franchise Peter Kellogg, Celgene Executive Vice President & Chief Financial Officer ? Transaction Overview Mark Kreston, Celgene Corporate Vice President, Glo |
|
| July 15, 2015 |
Exhibit 99.2 Celgene to Acquire Receptos, Advancing Leadership in Immune-Inflammatory Diseases Significantly Enhances Celgene?s I&I Franchise with the Addition of Ozanimod, Potentially a Best-in-Class Oral Agent in Phase III Trials for Inflammatory Bowel Disease and Multiple Sclerosis Accelerates Growth Beginning in 2019; Significant Growth Driver Beyond 2020 with Expected Ozanimod Peak Annual Sal |
|
| July 15, 2015 |
SC TO-C 1 t1501593sctoc.htm SCHEDULE TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 RECEPTOS, INC. (Name of Subject Company (Issuer)) STRIX CORPORATION (Offeror) A Wholly Owned Subsidiary of CELGENE CORPORATION (Parent of Offeror) (Names of Filing Persons (iden |
|
| July 15, 2015 |
SC TO-C 1 t15016238k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2015 Celgene Corporation (Exact name of registrant as specified in its charter) Delaware 001-34912 22-2711928 (State or other jurisdiction o |
|
| July 15, 2015 |
Exhibit 2.1 Execution Copy AGREEMENT AND PLAN OF MERGER by and among CELGENE CORPORATION, STRIX CORPORATION and RECEPTOS, INC. Dated as of July 14, 2015 TABLE OF CONTENTS Page Article I DEFINITIONS & INTERPRETATIONS 2 1.1 Certain Definitions 2 1.2 Additional Definitions 13 1.3 Certain Interpretations 15 Article II THE OFFER 16 2.1 The Offer 16 2.2 Company Actions 20 Article III THE MERGER 22 3.1 T |
|
| July 15, 2015 |
JPMorgan Chase Bank, N.A. J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 EX-10.1 3 t1501623ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 EXECUTION VERSION JPMorgan Chase Bank, N.A. J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 July 14, 2015 Project Strix US$5,000,000,000 Bridge Loan Facility Commitment Letter Celgene Corporation 400 Connell Park, 4th Floor Berkeley Heights, NJ 07922 Attention: Jonathan Biller Senior Vice President, Tax and Treasury Ladies and |
|
| July 14, 2015 |
SC14D9C 1 d37396dsc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RECEPTOS, INC. (Name of Subject Company) RECEPTOS, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 756207106 (CUS |
|
| July 14, 2015 |
EX-99.1 Exhibit 99.1 Celgene to Acquire Receptos, Advancing Leadership in Immune-Inflammatory Diseases Significantly Enhances Celgene?s I&I Franchise with the Addition of Ozanimod, Potentially a Best-in-Class Oral Agent in Phase III Trials for Inflammatory Bowel Disease and Multiple Sclerosis Accelerates Growth Beginning in 2019; Significant Growth Driver Beyond 2020 with Expected Ozanimod Peak An |
|
| July 14, 2015 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2015 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation) (Commission F |
|
| June 11, 2015 |
RCPT / Receptos, Inc. / Arch Venture Fund VII LP - RECEPTOS, INC. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Receptos, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 756207106 (CUSIP Number) Mark McDonnell ARCH Venture Corporation 8725 W. Higgins Road Suite 290 Chicago, IL 60631 (Name, Address and Telephone Number of Person |
|
| June 1, 2015 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): May 28, 2015 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organization |
|
| May 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 10-Q 1 d899427d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35900 |
|
| May 5, 2015 |
EX-99.1 2 d920769dex991.htm EX-99.1 Exhibit 99.1 Receptos Provides Business Update and Reports First Quarter 2015 Financial Results - Positive Phase 2 induction and maintenance results for TOUCHSTONE trial of ozanimod (formerly RPC1063) in Ulcerative Colitis (UC) support broad development program in UC, Crohn’s Disease - - Ongoing clinical trials enrolling on schedule - - Well capitalized, with ov |
|
| May 5, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): May 5, 2015 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organization) |
|
| April 17, 2015 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Pro |
|
| April 17, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 16, 2015 |
EX-99.1 Exhibit 99.1 Receptos Reports Positive Results for the Maintenance Period of the Phase 2 TOUCHSTONE Trial of Ozanimod in Ulcerative Colitis - Study met all efficacy endpoints with statistical significance for patients on 1 mg dose after 32 weeks of treatment - - Safety data are consistent with the favorable profile observed in prior clinical trials - - Receptos plans to accelerate initiati |
|
| April 16, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K 1 d912718d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): April 16, 2015 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorp |
|
| March 3, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d882721d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): March 3, 2015 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorpo |
|
| March 3, 2015 |
EX-99.1 Exhibit 99.1 Receptos Provides Development Updates and Reports Fourth Quarter and Year End 2014 Financial Results - Positive Phase 2 induction results for TOUCHSTONE trial of ozanimod (formerly RPC1063) in Ulcerative Colitis (UC) support initiation of broad development program in UC, Crohn’s Disease - - Both Phase 3 trials of ozanimod in Relapsing Multiple Sclerosis enrolling on schedule - |
|
| March 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K 10-K 1 d846329d10k.htm FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35900 (Exact Name |
|
| February 23, 2015 |
A Randomized, Double-Blind, Placebo-Controlled Induction EX-99.1 A Randomized, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator Ozanimod (RPC1063) in Moderate to Severe Ulcerative Colitis: Results of the TOUCHSTONE Study William Sandborn, MD 21 February 2015 Barcelona, Spain W. Sandborn¹, B. Feagan², D. Wolf³, G. D'Haens 4 , S. Vermeire 5 , S. Hanauer 6 , S. Ghosh 7 , H. Smith 8 , M. Cravets 8 , P. Frohna 8 , S. Gujrath |
|
| February 23, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): February 21, 2015 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organiz |
|
| February 18, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): February 13, 2015 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35900 (Commissi |
|
| February 18, 2015 |
EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is made as of July 30, 2014, by and between ARE-SD REGION NO. 35, LLC, a Delaware limited liability company (“Landlord”), and RECEPTOS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated as of April 22, 2014 (the “Lease”). |
|
| February 18, 2015 |
EX-10.2 Exhibit 10.2 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is made as of February 13, 2015, by and between ARE-SD REGION NO. 35, LLC, a Delaware limited liability company (“Landlord”), and RECEPTOS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated as of April 22, 2014, as amen |
|
| February 17, 2015 |
RCPT / Receptos, Inc. / LILLY ELI & CO - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) Receptos, Inc. (Name of lssuer) Common Stock; $0.001 par value (Title of Class of Securities) 756207106 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 17, 2015 |
SC 13G/A 1 sc13ga107422rec12312014.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Receptos, Inc. (Name of Issuer) Common Stock, par value $0.001 per |
|
| December 2, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): December 1, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organization) |
|
| November 24, 2014 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): November 24, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organization |
|
| November 24, 2014 |
EX-99.1 Exhibit 99.1 Receptos Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Underwritten Public Offering of Common Stock SAN DIEGO, November 24, 2014 - Receptos, Inc. (Nasdaq: RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today the completion of the previously anno |
|
| November 19, 2014 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): November 18, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organiz |
|
| November 19, 2014 |
Receptos Announces Pricing of Underwritten Public Offering of Common Stock EX-99.1 Exhibit 99.1 Receptos Announces Pricing of Underwritten Public Offering of Common Stock SAN DIEGO, November 18, 2014 - Receptos, Inc. (Nasdaq: RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public |
|
| November 19, 2014 |
3,600,000 RECEPTOS, INC. Common Stock UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 EXECUTION VERSION 3,600,000 RECEPTOS, INC. Common Stock UNDERWRITING AGREEMENT November 18, 2014 CREDIT SUISSE SECURITIES (USA) LLC LEERINK PARTNERS LLC As Representatives of the several Underwriters, c/o Credit Suisse Securities (USA) LLC, Eleven Madison Avenue, New York, NY 10010-3629 c/o Leerink Partners LLC, One Federal Street, 37th Floor, Boston, MA 02110-2015 Dear Sirs: 1. |
|
| November 19, 2014 |
424B5 Table of Contents CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be Registered(1) Proposed Maximum Offering Price per Share Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, $0. |
|
| November 17, 2014 |
SUBJECT TO COMPLETION, DATED NOVEMBER 17, 2014 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-197464 The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to |
|
| November 4, 2014 |
EX-99.1 2 d815154dex991.htm EX-99.1 Exhibit 99.1 Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results - Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease - - Enrollment in first Phase 3 trial of RPC1063 in RMS proceeding on schedule - - Receptos pla |
|
| November 4, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35900 RECEPTOS, INC. |
|
| November 4, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d815154d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): November 4, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of inco |
|
| October 27, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K 1 d811823d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): October 27, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of inco |
|
| October 27, 2014 |
EX-99.1 Exhibit 99.1 Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis – Study met primary efficacy and all secondary endpoints with statistical significance for patients on 1 mg dose after 8 weeks of treatment – – Safety data are consistent with the favorable profile observed in Phase 2 trial in relapsing multiple sclerosis – – Receptos plans to initi |
|
| September 19, 2014 |
EX-99.1 CUSIP No. 756207106 13D 1 6 of 17 Exhibit 1 AGREEMENT OF JOINT FILING Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Receptos, Inc. This Agreement may be executed |
|
| September 19, 2014 |
RCPT / Receptos, Inc. / Arch Venture Fund VII LP - SC 13D/A Activist Investment SC 13D/A 1 d791623dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Receptos, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 756207106 (CUSIP Number) Mark McDonnell ARCH Venture Corporation 8725 W. Higgins Road Suite 290 Chicago, IL 60631 (Name, |
|
| September 15, 2014 |
Phase 2 Results of the RADIANCE Trial: A Randomized, EX-99.1 Phase 2 Results of the RADIANCE Trial: A Randomized, Double-Blind, Placebo-Controlled Trial of Oral RPC1063 in Relapsing Multiple Sclerosis Amit Bar-Or, MD September 13, 2014 1 Cleveland Clinic, Mellen Center for MS Treatment and Research, Cleveland, OH, United States 2 NeuroRx Research, Montreal, QC, Canada 3 McGill University, Montreal, QC, Canada 4 San Raffaele Scientific Institute, Vit |
|
| September 15, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): September 13, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organizatio |
|
| August 22, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Receptos, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 756207106 (CUSIP Number) August 13, |
|
| August 22, 2014 |
EX-99.1 2 ex991to13g07422rec08132014.htm Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated August 22, 2014 with respect to the shares of Common Stock of Receptos, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provi |
|
| August 18, 2014 |
RCPT / Receptos, Inc. / Arch Venture Fund VII LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Receptos, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 756207106 (CUSIP Number) Mark McDonnell ARCH Venture Corporation 8725 W. Higgins Road Suite 290 Chicago, IL 60631 (Name, Address and Telephone Number of Person |
|
| August 18, 2014 |
EX-99.1 CUSIP No. 756207106 13D Exhibit 1 AGREEMENT OF JOINT FILING Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Receptos, Inc. This Agreement may be executed in any nu |
|
| August 12, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): August 12, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organization) |
|
| August 12, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35900 RECEPTOS, INC. |
|
| August 12, 2014 |
EX-99.1 Exhibit 99.1 Receptos Reports Second Quarter 2014 Financial Results - Completes enrollment of Phase 2 trial of RPC1063 in Ulcerative Colitis; data expected in fourth quarter of 2014 - - Announces oral platform presentation of Phase 2 data for RPC1063 in Relapsing Multiple Sclerosis at MS Boston 2014 - - Enrollment in Phase 3 trial of RPC1063 in Relapsing Multiple Sclerosis proceeding on sc |
|
| July 29, 2014 |
Receptos Announces Appointment of Mary Szela and Richard Heyman, Ph.D. to Board of Directors EX-99.1 2 d765177dex991.htm EX-99.1 Exhibit 99.1 Receptos Announces Appointment of Mary Szela and Richard Heyman, Ph.D. to Board of Directors San Diego, CA, July 29, 2014 — Receptos, Inc. (Nasdaq: RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the appointment of Mary Szela and Richard Heyman to the board of d |
|
| July 29, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): July 25, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organizatio |
|
| July 16, 2014 |
EX-4.8 EXHIBIT 4.8 RECEPTOS, INC. TO [ ] Trustee Indenture Dated as of l RECEPTOS, INC. Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of — Trust Indenture Act Section Indenture Sections § 310 (a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608 610 § 311 (a) 613(a) (b) 613(b) (b)(2) 703(a)(2) 703(b) § 312 (a) 701 702(a) (b) 702(b |
|
| July 16, 2014 |
STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES EX-12.1 EXHIBIT 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES The following table sets forth our ratio of earnings to fixed charges and ratio of earnings to combined fixed charges and preference security dividends for the periods indicated. As each of the ratios is less than one-to-one in each of the years presented, we have provided the coverage deficiency amounts for |
|
| July 16, 2014 |
RCPT / Receptos, Inc. S-3ASR - - S-3ASR S-3ASR Table of Contents As filed with the Securities and Exchange Commission on July 16, 2014 Registration No. |
|
| June 24, 2014 |
Receptos Announces Closing of Underwritten Public Offering of Common Stock EX-99.1 Exhibit 99.1 Receptos Announces Closing of Underwritten Public Offering of Common Stock SAN DIEGO, June 24, 2014 - Receptos, Inc. (Nasdaq: RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today closing of the previously announced underwritten public offering of 4,433,000 shares of its common stock at a price |
|
| June 24, 2014 |
Financial Statements and Exhibits, Other Events 8-K 1 d746043d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): June 24, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporatio |
|
| June 19, 2014 |
424B4 1 d743616d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Statement Nos. 333-196651 and 333-196888 Prospectus 4,433,000 Shares Common Stock Receptos, Inc. is offering 4,433,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Market under the symbol “RCPT.” On June 18, 2014, the last reported sale price of our common stock on The NAS |
|
| June 18, 2014 |
S-3MEF As filed with the Securities and Exchange Commission on June 18, 2014 Registration No. |
|
| June 17, 2014 |
[—] RECEPTOS, INC. Common Stock UNDERWRITING AGREEMENT EX-1.1 2 d743616dex11.htm EX-1.1 Exhibit 1.1 [—] RECEPTOS, INC. Common Stock UNDERWRITING AGREEMENT , 2014 CREDIT SUISSE SECURITIES (USA) LLC LEERINK PARTNERS LLC As Representatives of the several Underwriters, c/o Credit Suisse Securities (USA) LLC, Eleven Madison Avenue, New York, NY 10010-3629 c/o Leerink Partners LLC, One Federal Street, 37th Floor, Boston, MA 02110-2015 Dear Sirs: 1. Introduc |
|
| June 17, 2014 |
FORM S-3/A Table of Contents As filed with the Securities and Exchange Commission on June 17, 2014 Registration No. |
|
| June 11, 2014 |
FORM S-3 Table of Contents As filed with the Securities and Exchange Commission on June 11, 2014 Registration No. |
|
| June 11, 2014 |
REQUEST FOR WITHDRAWAL Receptos, Inc. 10835 Road to the Cure, Suite 205 San Diego, California 92121 June 11, 2014 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler Assistant Director Re: Receptos, Inc. – Request for Withdrawal of Registration Statement on Form S-3ASR (File No. 333-195946). Ladie |
|
| June 9, 2014 |
EX-99.1 2 d740435dex991.htm EX-99.1 Exhibit 99.1 Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis – Study met primary efficacy endpoint with statistical significance after 24 weeks of treatment – – Safety data are supportive of differentiated product profile – – Investor conference call and webcast today at 5:00 p.m. EDT (2:00 p.m. PDT) – San Diego, CA, June 9, |
|
| June 9, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): June 9, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organization |
|
| June 5, 2014 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): June 3, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organization) (Co |
|
| May 14, 2014 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 14, 2014 Registration No. |
|
| May 14, 2014 |
EX-4.8 2 d727648dex48.htm EX-4.8 EXHIBIT 4.8 RECEPTOS, INC. TO [ ] Trustee Indenture Dated as of l RECEPTOS, INC. Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of — Trust Indenture Act Section Indenture Sections § 310 (a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608 610 § 311 (a) 613(a) (b) 613(b) (b)(2) 703(a)(2) 703(b) § 31 |
|
| May 14, 2014 |
FORM S-8 As filed with the Securities and Exchange Commission on May 14, 2014 Registration No. |
|
| May 14, 2014 |
STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES EX-12.1 EXHIBIT 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES The following table sets forth our ratio of earnings to fixed charges and ratio of earnings to combined fixed charges and preference security dividends for the periods indicated. As each of the ratios is less than one-to-one in each of the years presented, we have provided the coverage deficiency amounts for |
|
| May 12, 2014 |
RECEPTOS, INC. 2013 STOCK INCENTIVE PLAN NOTICE OF STOCK UNIT AWARD Exhibit 10.2 RECEPTOS, INC. 2013 STOCK INCENTIVE PLAN NOTICE OF STOCK UNIT AWARD You have been granted the following Stock Units representing Common Stock of Receptos, Inc. (the “Company”) under the Company’s 2013 Stock Incentive Plan (the “Plan”). Name of Participant: [ ] Total Number of Stock Units Granted: [ ] Date of Grant: [ ] Vesting Commencement Date: [ ] Vesting Schedule: [One-fourth (1/4t |
|
| May 12, 2014 |
EX-99.1 Exhibit 99.1 Receptos Reports First Quarter 2014 Financial Results - Top-line results of Phase 2 trial of RPC1063 in relapsing multiple sclerosis expected in mid-2014 - - Phase 3 trial of RPC1063 in relapsing multiple sclerosis enrolling patients globally - - Results of Phase 2 trial of RPC1063 in ulcerative colitis expected in Q4 2014 - - Conference Call Today at 8:30 a.m. Eastern Time - |
|
| May 12, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35900 RECEPTOS, INC. |
|
| May 12, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): May 12, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organization |
|
| April 28, 2014 |
EX-10.1 2 d716894dex101.htm EX-10.1 Exhibit 10.1 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 22nd day of April, 2014, between ARE-SD REGION NO. 35, LLC, a Delaware limited liability company (“Landlord”), and RECEPTOS, INC., a Delaware corporation (“Tenant”). Building: 3033 Science Park Road, San Diego, California Premises: That certain portion of the 1st floor of the Building, |
|
| April 28, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): April 22, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organization) (Comm |
|
| April 23, 2014 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Pro |
|
| April 23, 2014 |
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Pro |
|
| April 14, 2014 |
Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director EX-99.1 2 d711206dex991.htm EX-99.1 Exhibit 99.1 Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director San Diego, CA, April 14, 2014 — Receptos, Inc. (Nasdaq: RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the appointment of Mary Lynne Hedley, Ph.D. as a director of Receptos. Dr. Hedley will |
|
| April 14, 2014 |
8-K 1 d711206d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): April 9, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorpo |
|
| March 6, 2014 |
Exhibit 10.40 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into effective as of November 25, 2013, by and between Receptos, Inc. (the “Company”) and Christian Waage (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties.” W I T N E S S E T H: A. The Company desires assurance of the association and services of Execu |
|
| March 6, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Use these links to rapidly review the document TABLE OF CONTENTS PART IV RECEPTOS, INC. |
|
| March 5, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): March 5, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35900 (Commission File |
|
| March 5, 2014 |
EX-99.1 2 a14-73601ex99d1.htm EX-99.1 Exhibit 99.1 Receptos Reports Fourth Quarter and Year End 2013 Operational and Financial Results - Favorable interim results from Phase 2 trial of RPC1063 in relapsing multiple sclerosis consistent with differentiated profile; top-line data expected mid-2014 - - Phase 3 trial of RPC1063 in relapsing multiple sclerosis has begun enrolling patients - - Top-line |
|
| February 20, 2014 |
RCPT / Receptos, Inc. / Flagship Ventures Fund 2007, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2014 |
RCPT / Receptos, Inc. / VENROCK ASSOCIATES V LP - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* RECEPTOS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 756207106 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 4, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): January 28, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35900 (Commission Fi |
|
| January 14, 2014 |
Exhibit 99.1 Receptos Announces Closing of Underwritten Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO, CA., January 14, 2014 - Receptos, Inc. (Nasdaq: RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today closing of the previously announced underwri |
|
| January 14, 2014 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): January 14, 2014 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35900 (Commission Fi |
|
| January 9, 2014 |
Use these links to rapidly review the document TABLE OF CONTENTS RECEPTOS, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Statement Nos. 333-193074 and 333-193239 Prospectus 3,320,000 Shares Common Stock Receptos, Inc. is offering 3,320,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Market under the s |
|
| January 9, 2014 |
As filed with the Securities and Exchange Commission on January 8, 2014 Registration No. |
|
| January 8, 2014 |
As filed with the Securities and Exchange Commission on January 8, 2014 Registration No. |
|
| January 6, 2014 |
RECEPTOS, INC. 10835 Road to the Cure, Suite 205 San Diego, California 92121 January 6, 2014 VIA ELECTRONIC SUBMISSION AND FACSIMILE Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Receptos, Inc. - Registration Statement — Form S-1 Registration Number: 333-193074 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C under the Se |
|
| January 6, 2014 |
CORRESP 1 filename1.htm January 6, 2014 VIA ELECTRONIC SUBMISSION Securities and Exchange Commission Mail Stop 3561 Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Austin Stephenson Re: Receptos, Inc. Registration Statement Filed on Form S-1 Registration No. 333-190374 Ladies and Gentlemen: In connection with the above-captioned Registration Statement, we wish to |
|
| January 6, 2014 |
[·] RECEPTOS, INC. Common Stock UNDERWRITING AGREEMENT EX-1.1 2 a2217837zex-11.htm EX-1.1 Exhibit 1.1 [·] RECEPTOS, INC. Common Stock UNDERWRITING AGREEMENT January [·], 2014 CREDIT SUISSE SECURITIES (USA) LLC LEERINK PARTNERS LLC As Representatives of the several Underwriters, c/o Credit Suisse Securities (USA) LLC, Eleven Madison Avenue, New York, NY 10010-3629 c/o Leerink Partners LLC, One Federal Street, 37th Floor, Boston, MA 02110-2015 Dear Sirs |
|
| January 6, 2014 |
Use these links to rapidly review the document TABLE OF CONTENTS RECEPTOS, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on January 6, 2014 Registration No. 333-193074 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REC |
|
| December 24, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS RECEPTOS, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on December 24, 2013 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RECEPTOS, INC. (Exact name |
|
| December 24, 2013 |
EX-10.14 2 a2217786zex-1014.htm EX-10.14 Exhibit 10.14 FOURTH AMENDMENT TO LEASE THIS FOURTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 30th day of September, 2013 (the “Execution Date”), by and between BMR-ROAD TO THE CURE LP, a Delaware limited partnership (“Landlord,” as successor-in-interest to BMR-10835 ROAD TO THE CURE LLC (“Original Landlord”)), and RECEPTOS, INC., a D |
|
| December 24, 2013 |
Exhibit 10.40 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into effective as of November 25, 2013, by and between Receptos, Inc. (the “Company”) and Christian Waage (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties.” W I T N E S S E T H: A. The Company desires assurance of the association and services of Execu |
|
| December 10, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): December 6, 2013 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35900 (Commission Fi |
|
| December 10, 2013 |
FIRST AMENDMENT TO COLLABORATION AGREEMENT Exhibit 10.1 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. *** Confidential material redacted and filed separately with the Commission. FIRST AMENDMENT TO COLLABORATION AGREEMENT This FIRST AMENDMENT (the “First Amendment”), dated as of December 6, 2013 (the “Amendment Date”), to that certain Collabor |
|
| December 10, 2013 |
Exhibit 99.1 Receptos and Ono Pharmaceuticals Expand Collaboration Agreement to Include Transfer of Receptos GPCR Technology Platform SAN DIEGO, CA, December 10, 2013 — Receptos, Inc. (Nasdaq:RCPT) announced today that Ono has elected to amend and expand the existing collaboration agreement between the parties to include transfer to Ono of the Receptos G-protein-coupled receptor (GPCR) technology |
|
| December 5, 2013 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): December 5, 2013 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35900 (Commission Fi |
|
| December 5, 2013 |
Exhibit 99.1 Receptos to Initiate Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis — Data from Interim Analysis of Phase 2 Trial Provide Support to Advance Program — — Interim Data Consistent with RPC1063 Differentiation Profile — SAN DIEGO, Dec. 5, 2013 (GLOBE NEWSWIRE) — Receptos, Inc. (Nasdaq:RCPT) announced today that the Company has completed a pre-planned interim analysis of the Phas |
|
| November 26, 2013 |
Christian Waage Appointed General Counsel of Receptos Exhibit 99.1 Christian Waage Appointed General Counsel of Receptos SAN DIEGO, CA, November 26, 2013 — Receptos, Inc. announced today that Christian Waage has been appointed Senior Vice President and General Counsel of the Company. Mr. Waage joins Receptos from Websense Inc., where he served as Vice President and General Counsel from 2012 until its acquisition in 2013. Prior to Websense, he served |
|
| November 26, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): November 26, 2013 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35900 (Commission F |
|
| November 25, 2013 |
RCPT / Receptos, Inc. / Flagship Ventures Fund 2007, L.P. - SC 13D/A Activist Investment SC 13D/A CUSIP No. 756207106 13D Page 1 of 10 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Receptos, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 756207106 (CUSIP Number) Noubar B. Afeyan, Ph.D. Flagship Ventures One Memorial Drive, 7th Floor Cam |
|
| November 21, 2013 |
receptosexhibit991forfor Exhibit 99.1 Reporting Owners Reporting Owner Name/Address Relationships Director 10% Ownership Officer Other Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 X Lilly Ventures Fund I, LLC 115 West Washington St. Suite 1680-South Indianapolis, IN 46204 X S. Edward Torres 115 West Washington St. Suite 1680-South Indianapolis, IN 46204 X* X *S. Edward Torre |
|
| November 21, 2013 |
EX-99.1 2 receptosinc-jointfilingagr.htm EXHIBIT Exhibit 99.1 The undersigned hereby agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G/A may be filed on behalf of each of the u |
|
| November 21, 2013 |
poalillyventuresfundi Lilly Ventures Fund I, LLC 115 West Washington Street Suite 1680-South Indianapolis, Indiana 46204 Securities and Exchange Commission Washington, D. |
|
| November 21, 2013 |
poasedwardtorres S. Edward Torres 115 West Washington Street Suite 1680-South Indianapolis, Indiana 46204 Securities and Exchange Commission Washington, D.C. 20549 Authorization Regarding Reporting Forms I hereby authorize and designate the following persons to sign and file with the Commission on my behalf Forms 3, 4 and 5 covering transactions and holdings in the common stock and other equity se |
|
| November 21, 2013 |
receptosexhibit991forfor Exhibit 99.1 Reporting Owners Reporting Owner Name/Address Relationships Director 10% Ownership Officer Other Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 X Lilly Ventures Fund I, LLC 115 West Washington St. Suite 1680-South Indianapolis, IN 46204 X S. Edward Torres 115 West Washington St. Suite 1680-South Indianapolis, IN 46204 X* X *S. Edward Torre |
|
| November 21, 2013 |
poalillyventuresfundi Lilly Ventures Fund I, LLC 115 West Washington Street Suite 1680-South Indianapolis, Indiana 46204 Securities and Exchange Commission Washington, D. |
|
| November 21, 2013 |
RCPT / Receptos, Inc. / LILLY ELI & CO - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Receptos, Inc. (Name of lssuer) Common Stock; $0.001 par value (Title of Class of Securities) 756207106 (CUSIP Number) May 14, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| November 21, 2013 |
poasedwardtorres S. Edward Torres 115 West Washington Street Suite 1680-South Indianapolis, Indiana 46204 Securities and Exchange Commission Washington, D.C. 20549 Authorization Regarding Reporting Forms I hereby authorize and designate the following persons to sign and file with the Commission on my behalf Forms 3, 4 and 5 covering transactions and holdings in the common stock and other equity se |
|
| October 31, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 10-Q 1 a13-19064110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001 |
|
| October 31, 2013 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.4 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into effective as of September 17, 2013, by and between Receptos, Inc. (the “Company”) and Robert J. Peach, Ph.D. (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties.” W I T N E S S E T H: A. The Company desires a |
|
| October 31, 2013 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into effective as of September 17, 2013, by and between Receptos, Inc. (the “Company”) and Graham Cooper (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties.” W I T N E S S E T H: A. The Company desires assurance |
|
| October 31, 2013 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.6 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into effective as of September 17, 2013, by and between Receptos, Inc. (the “Company”) and Chrysa Mineo (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties.” W I T N E S S E T H: A. The Company desires assurance o |
|
| October 31, 2013 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-10.5 6 a13-190641ex10d5.htm EX-10.5 Exhibit 10.5 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into effective as of September 17, 2013, by and between Receptos, Inc. (the “Company”) and Marcus F. Boehm, Ph.D. (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties.” W I T |
|
| October 31, 2013 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into effective as of September 17, 2013, by and between Receptos, Inc. (the “Company”) and Faheem Hasnain (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties.” W I T N E S S E T H: A. The Company desires assurance |
|
| October 31, 2013 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-10.3 4 a13-190641ex10d3.htm EX-10.3 Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into effective as of September 17, 2013, by and between Receptos, Inc. (the “Company”) and Sheila K. Gujrathi, M.D. (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties.” W I |
|
| October 30, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): October 30, 2013 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organization) (Co |
|
| October 30, 2013 |
Exhibit 99.1 Receptos Reports Third Quarter 2013 Financial Results - Phase 2 trial of RPC1063 in relapsing multiple sclerosis has completed enrollment; interim results to be reviewed in Q4 2013 - - Phase 2 trial of RPC1063 in ulcerative colitis continues to enroll patients globally - - Results of thorough QT Study recently presented at ECTRIMS - - Conference Call Today at 5 p.m. Eastern Time - San |
|
| September 18, 2013 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into effective as of September [ ], 2013, by and between Receptos, Inc. (the “Company”) and [ ] (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties.” W I T N E S S E T H: A. The Company desires assurance of the co |
|
| September 18, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): September 17, 2013 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-35900 (Commission |
|
| August 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35900 RECEPTOS, INC. |
|
| August 7, 2013 |
EX-99.1 2 a13-181581ex99d1.htm EX-99.1 Exhibit 99.1 Receptos Reports Second Quarter 2013 Financial Results - Phase 2 trials of RPC1063 continue to enroll patients globally - - Company capitalized to complete current Phase 2 trials - - Additional Phase 1 results of RPC1063 to be presented at ECTRIMS - - Conference Call Today at 5 p.m. Eastern Time - San Diego, CA, August 7, 2013 — Receptos, Inc. (N |
|
| August 7, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): August 7, 2013 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organization) (Comm |
|
| July 22, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): July 17, 2013 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organization) (Commi |
|
| July 22, 2013 |
Receptos Announces Appointment of Erle T. Mast as Director EX-99.1 2 a13-169271ex99d1.htm EX-99.1 Exhibit 99.1 Receptos Announces Appointment of Erle T. Mast as Director San Diego, CA, July 22, 2013 — Receptos, Inc. (Nasdaq: RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the appointment of Erle T. Mast as a director of the Company. Mr. Mast will serve as a Class I di |
|
| June 24, 2013 |
S-8 1 a13-154521s8.htm S-8 As filed with the Securities and Exchange Commission on June 24, 2013 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 26 |
|
| June 20, 2013 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RECEPTOS, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RECEPTOS, INC. Receptos, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: FIRST: The name of the corporation is Receptos, Inc. SECOND: The original Certificate of Incorporation of the corporation was filed with the Secretary of State of the State of Delaware on September |
|
| June 20, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35900 RECEPTOS, INC. |
|
| June 20, 2013 |
AMENDED AND RESTATED B Y L A W S RECEPTOS, INC. (a Delaware corporation) Exhibit 3.2 AMENDED AND RESTATED B Y L A W S OF RECEPTOS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE 1 Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE 2 Meeting of Stockholders 1 2.1 Place of Meeting 1 2.2 Annual Meeting 1 2.3 Special Meetings 2 2.4 Notice of Meetings 3 2.5 List of Stockholders 3 2.6 Organization and Conduct of Business 3 2.7 Quorum 3 2.8 Adjournmen |
|
| June 5, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange act of 1934 Date of report (date of earliest event reported): June 5, 2013 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35900 26-4190792 (State or other jurisdiction of incorporation or organization) (Commis |
|
| June 5, 2013 |
EX-99.1 2 a13-143861ex99d1.htm EX-99.1 Exhibit 99.1 Jefferies 2013 Global Healthcare Conference Faheem Hasnain President and Chief Executive Officer June 5, 2013 Forward-Looking Statements All statements in this presentation other than those of historical fact, including statements regarding our clinical development plans for RPC1063 and RPC4046, our research and other development programs, projec |
|
| May 20, 2013 |
RCPT / Receptos, Inc. / Flagship Ventures Fund 2007, L.P. - SC 13D Activist Investment SC 13D 1 d540524dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Receptos, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 756207106 (CUSIP Number) Noubar B. Afeyan, Ph.D. Flagship Ventures One Memorial Drive, 7th Floor Cambridge, Massachuset |
|
| May 20, 2013 |
EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13D jointly on behalf of each such party. FLAGSHIP VENTURES FUND 2007, L.P |
|
| May 17, 2013 |
RCPT / Receptos, Inc. / Lilly Ventures Fund I LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Receptos, Inc. (Name of Issuer) Common Stock; $0.001 par value (Title of Class of Securities) 756207106 (CUSIP Number) May 14, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| May 17, 2013 |
RCPT / Receptos, Inc. / Arch Venture Fund VII LP - RECEPTOS, INC. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Receptos, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 756207106 (CUSIP Number) Mark McDonnell ARCH Venture Corporation 8725 W. Higgins Road Suite 290 Chicago, IL 60631 (Name, Address and Telephone Number of Person A |
|
| May 9, 2013 |
As filed with the Securities and Exchange Commission on May 9, 2013 Registration No. |
|
| May 9, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents Filed Pursuant to Rule 424(b)(4) Registsration Statement No. |
|
| May 6, 2013 |
CORRESP 1 filename1.htm May 6, 2013 VIA ELECTRONIC SUBMISSION Securities and Exchange Commission Mail Stop 3561 Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Karen Ubell Re: Receptos, Inc. Registration Statement Filed on Form S-1 Registration No. 333-187737 Ladies and Gentlemen: In connection with the above-captioned Registration Statement, we wish to advise th |
|
| May 6, 2013 |
CORRESP 1 filename1.htm RECEPTOS, INC. 10835 Road to the Cure, Suite 205 San Diego, California 92121 May 6, 2013 VIA ELECTRONIC SUBMISSION AND FACSIMILE Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Receptos, Inc. - Registration Statement – Form S-1 Registration Number: 333-187737 Ladies and Gentlemen: Pursuant to Rule 461 of Regul |
|
| April 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 RECEPTOS, INC. (Exact name of registrant as specified in its charter) Delaware 26-4190792 (State of incorporation or organization) (I.R.S. Employer Identification No.) 10835 Road to the Cure, Sui |
|
| April 25, 2013 |
EX-3.1(B) 3 a2214558zex-31b.htm EX-3.1(B) Exhibit 3.1(b) CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RECEPTOS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Receptos, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corp |
|
| April 25, 2013 |
Exhibit 4.1 COMMON STOCK CUSIP 756207 10 6 SEE REVERSE FOR CERTAIN DEFINITIONS Countersigned and Registered: AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC (Brooklyn, N.Y.) Transfer Agent and Registrar By Authorized Signature FULLY PAID AND NON-ASSESSABLE SHARES OF THE COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF VICE PRESIDENT, FINANCE AND ADMINISTRATION PRESIDENT AND CHIEF EXECUTIVE OFFICER transf |
|
| April 25, 2013 |
RECEPTOS, INC. 2008 STOCK PLAN EX-10.2 7 a2214558zex-102.htm EX-10.2 Exhibit 10.2 RECEPTOS, INC. 2008 STOCK PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants and to promote the success of the Company’s business. The Plan permits the grant of Options and |
|
| April 25, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on April 25, 2013 Registration No. |
|
| April 25, 2013 |
EX-10.5 8 a2214466zex-105.htm EX-10.5 Exhibit 10.5 RECEPTOS, INC. 2013 STOCK INCENTIVE PLAN (Adopted by the Board of Directors on April 18, 2018) (Approved by the Stockholders on April 18, 2018) RECEPTOS, INC. 2013 STOCK INCENTIVE PLAN Table of Contents Page SECTION 1. ESTABLISHMENT AND PURPOSE 1 SECTION 2. DEFINITIONS 1 (a) “Affiliate” 1 (b) “Award” 1 (c) “Award Agreement” 1 (d) “Board of Directo |
|
| April 25, 2013 |
Exhibit 10.41 PLEDGE AGREEMENT THIS PLEDGE AGREEMENT (this “Agreement”) is made as of April 19, 2013, by and between RECEPTOS, INC., a Delaware corporation (“Pledgor”), and MIDCAP FUNDING III, LLC, a Delaware limited liability company, as agent (in such capacity, together with its successors and assigns, “Agent”) for itself and the other Lenders (as defined herein). RECITALS A. The term “Borrowers |
|
| April 25, 2013 |
RECEPTOS, INC. EMPLOYEE STOCK PURCHASE PLAN EX-10.7 9 a2214466zex-107.htm EX-10.7 Exhibit 10.7 RECEPTOS, INC. EMPLOYEE STOCK PURCHASE PLAN Table of Contents Page SECTION 1 Purpose Of The Plan 1 SECTION 2 Definitions 1 (a) “Board” 1 (b) “Code” 1 (c) “Committee” 1 (d) “Company” 1 (e) “Compensation” 1 (f) “Corporate Reorganization” 1 (g) “Eligible Employee” 1 (h) “Exchange Act” 2 (i) “Fair Market Value” 2 (j) “IPO” 2 (k) “Offering” 2 (l) “Offe |
|
| April 25, 2013 |
Exhibit 10.42 SECURED PROMISSORY NOTE $30,000,000.00 April 19, 2013 FOR VALUE RECEIVED, RECEPTOS, INC., a Delaware corporation and APOPTOS, INC., a Delaware corporation (collectively, “Borrower”) hereby promises to pay to MIDCAP FUNDING III, LLC, a Delaware limited liability company or its registered assigns (“Lender”), with an address of 7255 Woodmont Avenue, Suite 200, Bethesda, Maryland 20814, |
|
| April 25, 2013 |
[Insert Number of Shares] RECEPTOS, INC. Common Stock UNDERWRITING AGREEMENT EX-1.1 2 a2214558zex-11.htm EX-1.1 Exhibit 1.1 [Insert Number of Shares] RECEPTOS, INC. Common Stock UNDERWRITING AGREEMENT [ ], 2013 CREDIT SUISSE SECURITIES (USA) LLC LEERINK SWANN LLC As Representatives of the several Underwriters, c/o Credit Suisse Securities (USA) LLC, Eleven Madison Avenue, New York, NY 10010-3629 c/o Leerink Swann LLC, One Federal Street, 37th Floor, Boston, MA 02110-2015 D |
|
| April 25, 2013 |
EX-10.40 10 a2214558zex-1040.htm EX-10.40 Exhibit 10.40 CREDIT AND SECURITY AGREEMENT THIS CREDIT AND SECURITY AGREEMENT (this “Agreement”), dated as of April 19, 2013 (the “Closing Date”) by and among MIDCAP FUNDING III, LLC, a Delaware limited partnership (“MidCap”), as administrative agent (“Agent”), the Lenders listed on the Credit Facility Schedule attached hereto and otherwise party hereto f |
|
| April 25, 2013 |
FORM OF OMNIBUS ACKNOWLEDGMENT AND AGREEMENT WITH RESPECT TO POTENTIAL INITIAL PUBLIC OFFERING Exhibit 4.8 FORM OF OMNIBUS ACKNOWLEDGMENT AND AGREEMENT WITH RESPECT TO POTENTIAL INITIAL PUBLIC OFFERING This Omnibus Acknowledgment and Agreement (this “Acknowledgment”) is made as of April 18, 2013, by and among Receptos, Inc., a Delaware corporation (the “Company”), and the stockholders of the Company tendering signature pages hereto with respect to the anticipated first underwritten public o |
|
| April 24, 2013 |
Pillsbury Winthrop Shaw Pittman LLP 12255 El Camino Real, Suite 300 | San Diego, CA 92130-4088 | tel 619. |
|
| April 22, 2013 |
CORRESP 1 filename1.htm Pillsbury Winthrop Shaw Pittman LLP 12255 El Camino Real, Suite 300 | San Diego, CA 92130-4088 | tel 619.234.5000 | fax 858.509.4010 Mike Hird tel 858.509.4024 [email protected] FOIA CONFIDENTIAL TREATMENT REQUEST Pursuant to 17 C.F.R. § 200.83 April 22, 2013 VIA EDGAR AND FAX U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E |
|
| April 18, 2013 |
CORRESP 1 filename1.htm Pillsbury Winthrop Shaw Pittman LLP 12255 El Camino Real, Suite 300 | San Diego, CA 92130-4088 | tel 619.234.5000 | fax 858.509.4010 Mike Hird tel 858.509.4024 [email protected] *** Confidential material redacted and filed separately with the Securities and Exchange Commission FOIA CONFIDENTIAL TREATMENT REQUESTED Pursuant to 17 C.F.R. § 200.83 April 14, 2013 Confi |
|
| April 16, 2013 |
EX-3.1B 2 a2214466zex-31b.htm EX-3.1B Exhibit 3.1b FORM OF CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RECEPTOS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Receptos, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Co |
|
| April 16, 2013 |
RECEPTOS CONFIDENTIAL COLLABORATION AGREEMENT Exhibit 10.18 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. *** Confidential material redacted and filed separately with the Commission. RECEPTOS CONFIDENTIAL COLLABORATION AGREEMENT This Collaboration Agreement (the “Agreement”) is made as of December 20, 2010 (the “Effective Date”) by and between Re |
|
| April 16, 2013 |
FORM OF AMENDED AND RESTATED B Y L A W S RECEPTOS, INC. (a Delaware corporation) EX-3.2B 4 a2214466zex-32b.htm EX-3.2B Exhibit 3.2b FORM OF AMENDED AND RESTATED B Y L A W S OF RECEPTOS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE 1 Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE 2 Meeting of Stockholders 1 2.1 Place of Meeting 1 2.2 Annual Meeting 1 2.3 Special Meetings 2 2.4 Notice of Meetings 3 2.5 List of Stockholders 3 2.6 Organization and Co |
|
| April 16, 2013 |
EX-10.17 10 a2214242zex-1017.htm EX-10.17 Exhibit 10.17 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. LICENSE AGREEMENT by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation and RECEPTOR PHARMACEUTICALS, INC., a Delaware corporation EXECUTION COPY 1 *** Confi |
|
| April 16, 2013 |
Exhibit 10.22 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. *** Confidential material redacted and filed separately with the Commission. COLLABORATION AGREEMENT This Collaboration Agreement (the “Agreement”) is made as of December 5, 2011 (the “Effective Date”) by and between Receptos, Inc. (“Receptos |
|
| April 16, 2013 |
Exhibit 10.23 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. CONFIDENTIAL DEVELOPMENT LICENSE AND OPTION AGREEMENT between ABBVIE BAHAMAS LTD., ABBVIE INC. and RECEPTOS, INC. Dated as of October 3, 2012 EXECUTION COPY i DEVELOPMENT LICENSE AND OPTION AGREEMENT This Development License and Option Agreem |
|
| April 16, 2013 |
Exhibit 10.5 FORM OF RECEPTOS, INC. 2013 STOCK INCENTIVE PLAN (Adopted by the Board of Directors on ) (Approved by the Stockholders on ) Table of Contents Page SECTION 1. ESTABLISHMENT AND PURPOSE 1 SECTION 2. DEFINITIONS 1 (a) “Affiliate” 1 (b) “Award” 1 (c) “Award Agreement” 1 (d) “Board of Directors” 1 (e) “Cash-Based Award” 1 (f) “Change in Control” 1 (g) “Code” 3 (h) “Committee” 3 (i) “Compan |
|
| April 16, 2013 |
FORM OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RECEPTOS, INC. Exhibit 3.1c FORM OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RECEPTOS, INC. Receptos, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: FIRST: The name of the corporation is Receptos, Inc. SECOND: The original Certificate of Incorporation of the corporation was filed with the Secretary of State of the State of Delaware on |
|
| April 16, 2013 |
FORM OF RECEPTOS, INC. EMPLOYEE STOCK PURCHASE PLAN Exhibit 10.7 FORM OF RECEPTOS, INC. EMPLOYEE STOCK PURCHASE PLAN Table of Contents Page SECTION 1 Purpose Of The Plan 1 SECTION 2 Definitions 1 (a) “Board” 1 (b) “Code” 1 (c) “Committee” 1 (d) “Company” 1 (e) “Compensation” 1 (f) “Corporate Reorganization” 1 (g) “Eligible Employee” 1 (h) “Exchange Act” 2 (i) “Fair Market Value” 2 (j) “IPO” 2 (k) “Offering” 2 (l) “Offering Date” 2 (m) “Offering Per |
|
| April 16, 2013 |
FORM OF RECEPTOS, INC. 2013 STOCK INCENTIVE PLAN NOTICE OF STOCK OPTION GRANT Exhibit 10.6 FORM OF RECEPTOS, INC. 2013 STOCK INCENTIVE PLAN NOTICE OF STOCK OPTION GRANT You have been granted the following Option to purchase Common Stock of Receptos, Inc. (the “Company”) under the Company’s 2013 Stock Incentive Plan (the “Plan”): Name of Optionee: [Name of Optionee] Total Number of Option Shares Granted: [Total Number of Shares] Type of Option: Incentive Stock Option Nonstat |
|
| April 16, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on April 15, 2013 Registration No. |
|
| April 16, 2013 |
RECEPTOS CONFIDENTIAL LICENSE AND TECHNOLOGY TRANSFER AGREEMENT EX-10.21 12 a2214242zex-1021.htm EX-10.21 Exhibit 10.21 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. RECEPTOS CONFIDENTIAL LICENSE AND TECHNOLOGY TRANSFER AGREEMENT This License and Technology Transfer Agreement (the “Agreement”) is made as of December 28, 2010 (the “Effective Date”) by and between R |
|
| April 16, 2013 |
Exhibit 10.14 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. LICENSE AGREEMENT by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation and RECEPTOS, INC., a Delaware corporation *** Confidential material redacted and filed separately with the Commission. LICENSE |
|
| April 16, 2013 |
FORM OF INDEMNIFICATION AGREEMENT Exhibit 10.1 FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement (the “Agreement”), dated as of , 2013, between Receptos, Inc., a Delaware corporation (the “Corporation”), and (“Indemnitee”), W I T N E S S E T H: WHEREAS, Indemnitee is either a member of the board of directors of the Corporation (the “Board of Directors”) or an officer of the Corporation, or both, and in such capacity |
|
| April 15, 2013 |
Pillsbury Winthrop Shaw Pittman LLP 12255 El Camino Real, Suite 300 | San Diego, CA 92130-4088 | tel 619. |
|
| April 4, 2013 |
RECEPTOS, INC. 2008 STOCK PLAN STOCK OPTION AGREEMENT EX-10.3 11 a2214242zex-103.htm EX-10.3 Exhibit 10.3 RECEPTOS, INC. 2008 STOCK PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2008 Stock Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”). I. NOTICE OF STOCK OPTION GRANT Name: Address: The undersigned Participant has been granted an Option to purchase |
|
| April 4, 2013 |
EX-3.1(A) 2 a2214242zex-31a.htm EX-3.1(A) Exhibit 3.1(a) AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RECEPTOS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Receptos, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES |
|
| April 4, 2013 |
RECEPTOS, INC. 10835 Road to the Cure, #205 San Diego, CA 92121 EX-10.26 31 a2214122zex-1026.htm EX-10.26 Exhibit 10.26 RECEPTOS, INC. 10835 Road to the Cure, #205 San Diego, CA 92121 February 6, 2013 Mr. Graham Cooper 17 Selborne Drive Piedmont, CA 94611 Re: Offer of Employment with Receptos, Inc. Dear Graham: Receptos, Inc. (the “Company”) is very pleased to offer you employment as its Chief Financial Officer (“CFO”) beginning on February 7, 2013. This offer |
|
| April 4, 2013 |
FIRST AMENDMENT TO COLLABORATION AGREEMENT EX-10.19 24 a2214242zex-1019.htm EX-10.19 Exhibit 10.19 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. *** Confidential material redacted and filed separately with the Commission. FIRST AMENDMENT TO COLLABORATION AGREEMENT This AMENDMENT (the “Amendment”), dated as of March 14, 2011, to that certain Co |
|
| April 4, 2013 |
EX-10.14 19 a2214242zex-1014.htm EX-10.14 Exhibit 10.14 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. LICENSE AGREEMENT by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation and RECEPTOS, INC., a Delaware corporation *** Confidential material redacted and fil |
|
| April 4, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on April 4, 2013 Registration No. |
|
| April 4, 2013 |
THIRD AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT EX-4.7 9 a2214242zex-47.htm EX-4.7 Exhibit 4.7 THIRD AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT THIS THIRD AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT is made as of February 3, 2012, by and among RECEPTOS, INC., a Delaware corporation (the “Company”), each Investor (as defined below) and each Key Holder (as defined below). RECITALS WHEREAS, the Company |
|
| April 4, 2013 |
Exhibit 10.12 ASSIGNMENT THIS ASSIGNMENT (this “Assignment”), entered into as of June 8, 2010, by and between APOPTOS, INC., a Delaware corporation (“Apoptos”), and RECEPTOS, INC., a Delaware corporation (“Receptos”), is made with reference to the following facts: A. BMR-10835 ROAD TO THE CURE LLC, a Delaware limited liability company (“Landlord”), and Apoptos have entered into that certain Lease |
|
| April 4, 2013 |
APPROVAL WITH RESPECT TO SERIES B PREFERRED STOCK PURCHASE AGREEMENT EX-4.6 8 a2214242zex-46.htm EX-4.6 Exhibit 4.6 APPROVAL WITH RESPECT TO SERIES B PREFERRED STOCK PURCHASE AGREEMENT This Approval (this “Approval”) is made as of March 6, 2012, by and among RECEPTOS, INC., a Delaware corporation (the “Company”), the New Party (as defined below), and the stockholders of the Company tendering signature pages hereto with respect to that certain Series B Preferred Sto |
|
| April 4, 2013 |
Exhibit 10.17 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. LICENSE AGREEMENT by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation and RECEPTOR PHARMACEUTICALS, INC., a Delaware corporation EXECUTION COPY 1 *** Confidential material redacted and filed separa |
|
| April 4, 2013 |
Exhibit 4.4 OMNIBUS APPROVAL AND AMENDMENT WITH RESPECT TO: SERIES B PREFERRED STOCK PURCHASE AGREEMENT; AND THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT This Omnibus Approval and Amendment (this “Amendment”) is made as of February 23, 2012, by and among RECEPTOS, INC., a Delaware corporation (the “Company”), the New Party (as defined below), and the stockholders of the Company tendering |
|
| April 4, 2013 |
WARRANT TO PURCHASE COMMON STOCK RECEPTOS, INC. Exhibit 4.2 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES PURSUANT TO REGISTRATION OR AN EXEMPTION THEREFROM |
|
| April 4, 2013 |
AMENDED AND RESTATED CONSULTING AGREEMENT EX-10.38 43 a2214122zex-1038.htm EX-10.38 Exhibit 10.38 AMENDED AND RESTATED CONSULTING AGREEMENT This is to confirm the agreement between DISA Consulting, LLC, a California company (“DISA”), and Receptos, Inc., a Delaware corporation (the “Company”), for consulting services (the “Agreement”). Whereas, Hugh Rosen (“Consultant”) is the sole member of, and owns all interests in,. DISA and Consultant |
|
| April 4, 2013 |
Exhibit 10.28 RECEPTOS, INC. May 11, 2009 Marcus Boehm Re: Offer of Employment with Receptos, Inc. Dear Marcus: Receptos, Inc. (the “Company”) is very pleased to offer you employment as its Vice President of Chemistry beginning immediately following the effective time of the combination (through a subsidiary merger) of the Company (formerly known as Receptor Pharmaceuticals, Inc.) and Apoptos, Inc |
|
| April 4, 2013 |
EX-10.23 28 a2214242zex-1023.htm EX-10.23 Exhibit 10.23 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. CONFIDENTIAL DEVELOPMENT LICENSE AND OPTION AGREEMENT between ABBVIE BAHAMAS LTD., ABBVIE INC. and RECEPTOS, INC. Dated as of October 3, 2012 EXECUTION COPY i DEVELOPMENT LICENSE AND OPTION AGREEMENT |
|
| April 4, 2013 |
Exhibit 10.13 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 6th day of January, 2012 (the “Execution Date”), by and between BMR-ROAD TO THE CURE LP, a Delaware limited partnership (“Landlord,” as successor-in-interest to BMR-10835 ROAD TO THE CURE LLC, a Delaware limited liability company (“Original Landlord”), and RECEPTOS, INC., a Delaware c |
|
| April 4, 2013 |
AMENDED AND RESTATED SECOND AMENDMENT TO LEASE EX-10.11 16 a2214242zex-1011.htm EX-10.11 Exhibit 10.11 AMENDED AND RESTATED SECOND AMENDMENT TO LEASE THIS AMENDED AND RESTATED SECOND AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 15th day of September, 2009, by and between BMR-10835 ROAD TO THE CURE LLC, a Delaware limited liability company (“Landlord”), and APOPTOS, INC., a Delaware corporation (“Tenant”). RECITALS A. WHEREA |
|
| April 4, 2013 |
Pillsbury Winthrop Shaw Pittman LLP 12255 El Camino Real, Suite 300 | San Diego, CA 92130-4088 | tel 619. |
|
| April 4, 2013 |
Exhibit 10.8 EXECUTION VERSION LEASE by and between BMR-10835 ROAD TO THE CURE LLC, a Delaware limited liability company and APOPTOS, INC., a Delaware corporation LEASE THIS LEASE (this “Lease”) is entered into as of this 24th day of August, 2007 (the “Execution Date”), by and between BMR-10835 ROAD TO THE CURE LLC, a Delaware limited liability company (“Landlord”), and APOPTOS, INC., a Delaware c |
|
| April 4, 2013 |
RECEPTOS, INC. 2008 STOCK PLAN STOCK OPTION AGREEMENT — EARLY EXERCISE Exhibit 10.4 RECEPTOS, INC. 2008 STOCK PLAN STOCK OPTION AGREEMENT — EARLY EXERCISE Unless otherwise defined herein, the terms defined in the 2008 Stock Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement — Early Exercise (the “Option Agreement”). I. NOTICE OF STOCK OPTION GRANT Name: Address: The undersigned Participant has been granted an Option to purchase Comm |
|
| April 4, 2013 |
EX-10.39 44 a2214122zex-1039.htm EX-10.39 Exhibit 10.39 CONSULTING AGREEMENT This is to confirm the agreement between Raymond Stevens (“Consultant”), and Receptos, Inc. (formerly known as Receptor Pharmaceuticals, Inc.), a Delaware corporation (the “Company”), for consulting services (the “Agreement”). The terms and conditions of the arrangements between Consultant and the Company are as follows: |
|
| April 4, 2013 |
RECEPTOS, INC. RESTRICTED STOCK ISSUANCE AGREEMENT (Faheem Hasnain) Exhibit 10.32 RECEPTOS, INC. RESTRICTED STOCK ISSUANCE AGREEMENT (Faheem Hasnain) THIS RESTRICTED STOCK ISSUANCE AGREEMENT (this “Agreement”) is made as of November 19, 2010 by and between Receptos, Inc., a Delaware corporation (the “Company”), and Faheem Hasnain, an individual (the “Stockholder”). THE PARTIES HEREBY AGREE AS FOLLOWS: 1. Issuance of Shares. 1.1 Issuance. The Company hereby issues |
|
| April 4, 2013 |
RECEPTOS, INC. 10835 Road to the Cure, #205 San Diego, CA 92121 Exhibit 10.30 RECEPTOS, INC. 10835 Road to the Cure, #205 San Diego, CA 92121 July 27, 2009 By email ([email protected]) Chrysa Mineo 3749 Elliott Street San Diego, CA 92106 Re: Offer of Employment with Receptos, Inc. Dear Chrysa: Receptos, Inc. (the “Company”) is very pleased to offer you employment as its Vice President of Business Development beginning on a part-time basis by July 30, 2009, |
|
| April 4, 2013 |
SECOND AMENDMENT TO COLLABORATION AGREEMENT Exhibit 10.20 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. *** Confidential material redacted and filed separately with the Commission. SECOND AMENDMENT TO COLLABORATION AGREEMENT This SECOND AMENDMENT (the “Second Amendment”), dated as of March 1, 2011, to that certain Collaboration Agreement dated |
|
| April 4, 2013 |
RECEPTOS, INC. RESTRICTED STOCK ISSUANCE AGREEMENT (Marcus Boehm) EX-10.36 41 a2214242zex-1036.htm EX-10.36 Exhibit 10.36 RECEPTOS, INC. RESTRICTED STOCK ISSUANCE AGREEMENT (Marcus Boehm) THIS RESTRICTED STOCK ISSUANCE AGREEMENT (this “Agreement”) is made as of July 30, 2009 by and between Receptos, Inc., a Delaware corporation (the “Company”), and Marcus Boehm, an individual (the “Stockholder”). THE PARTIES HEREBY AGREE AS FOLLOWS: 1. Issuance of Shares. 1.1 Is |
|
| April 4, 2013 |
RECEPTOS, INC. 10835 Road to the Cure San Diego, CA 92121 May 11, 2009 EX-10.31 36 a2214242zex-1031.htm EX-10.31 Exhibit 10.31 RECEPTOS, INC. 10835 Road to the Cure San Diego, CA 92121 May 11, 2009 James R. Schmidt 16052 Lofty Trail Drive San Diego, CA 92127 Dear Jim: On behalf of Receptos, Inc. (the “Company”), I am pleased to offer you the full-time position of Senior Director, Finance and Operations. This letter embodies the terms of our offer of employment to you |
|
| April 4, 2013 |
FIRST AMENDMENT TO DEVELOPMENT LICENSE AND OPTION AGREEMENT EX-10.24 29 a2214242zex-1024.htm EX-10.24 Exhibit 10.24 FIRST AMENDMENT TO DEVELOPMENT LICENSE AND OPTION AGREEMENT This First Amendment to Development License and Option Agreement (this “First Amendment”) is entered into as of January 28, 2013 (the “First Amendment Effective Date”), by and between AbbVie Inc., a corporation of the state of Delaware, having its principal place of business at 1 Nor |
|
| April 4, 2013 |
Exhibit 10.22 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. *** Confidential material redacted and filed separately with the Commission. COLLABORATION AGREEMENT This Collaboration Agreement (the “Agreement”) is made as of December 5, 2011 (the “Effective Date”) by and between Receptos, Inc. (“Receptos |
|
| April 4, 2013 |
Exhibit 21.1 SUBSIDIARIES Name Jurisdiction of Organization Apoptos, Inc. Delaware |
|
| April 4, 2013 |
AMENDED AND RESTATED CONSULTING AGREEMENT EX-10.37 42 a2214122zex-1037.htm EX-10.37 Exhibit 10.37 AMENDED AND RESTATED CONSULTING AGREEMENT This is to confirm the agreement between Edward Roberts (“Consultant”), and Receptos, Inc., a Delaware corporation (the “Company”), for consulting services (the “Agreement”). Whereas, Consultant and the Company are parties to that certain Consulting Agreement, deemed to have commenced May 11, 2009 (th |
|
| April 4, 2013 |
RECEPTOR PHARMACEUTICALS, INC. COMMON STOCK PURCHASE AGREEMENT Exhibit 10.34 RECEPTOR PHARMACEUTICALS, INC. COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (the “Agreement”) is made as of January 20, 2009 by and between Receptor Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Kristina Burow (the “Purchaser”). In consideration of the mutual covenants and representations set forth below, the Company and Purchaser agree as |
|
| April 4, 2013 |
RECEPTOS CONFIDENTIAL LICENSE AND TECHNOLOGY TRANSFER AGREEMENT Exhibit 10.21 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. RECEPTOS CONFIDENTIAL LICENSE AND TECHNOLOGY TRANSFER AGREEMENT This License and Technology Transfer Agreement (the “Agreement”) is made as of December 28, 2010 (the “Effective Date”) by and between Receptos, Inc., a Delaware corporation (“Re |
|
| April 4, 2013 |
AMENDMENT TO LICENSE AGREEMENT EX-10.16 21 a2214242zex-1016.htm EX-10.16 Exhibit 10.16 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. AMENDMENT TO LICENSE AGREEMENT THIS AMENDMENT (“Amendment”) to that certain LICENSE AGREEMENT dated June 18, 2009 (“License Agreement”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California non |
|
| April 4, 2013 |
THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Exhibit 4.3 THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT is made as of February 3, 2012, by and among RECEPTOS, INC., a Delaware corporation (the “Company”) and each of the parties listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.” RECITALS WHEREAS, the Company previously entered into t |
|
| April 4, 2013 |
Exhibit 10.9 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 30th day of March, 2008, by and between BMR-10835 ROAD TO THE CURE LLC, a Delaware limited liability company (“Landlord”), and APOPTOS, INC., a Delaware corporation (“Tenant”). RECITALS A. WHEREAS, Landlord and Tenant entered into that certain Lease dated as of August 24, 2007 (the “Le |
|
| April 4, 2013 |
RECEPTOS, INC. 2008 STOCK PLAN EX-10.2 10 a2214122zex-102.htm EX-10.2 Exhibit 10.2 RECEPTOS, INC. 2008 STOCK PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants and to promote the success of the Company’s business. The Plan permits the grant of Options an |
|
| April 4, 2013 |
